Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Trulieve Cannabis ( (TSE:TRUL) ) has issued an update.
Trulieve Cannabis welcomed the Trump Administration’s decision to reclassify marijuana as a Schedule III substance under the Controlled Substances Act, calling it a historic step toward practical cannabis reform that acknowledges the medical value of marijuana while supporting regulated operators. The company highlighted that rescheduling will ease restrictions on U.S.-based medical cannabis research and eliminate the punitive impact of Section 280E on state-legal businesses, potentially improving profitability for compliant operators while preserving law enforcement’s ability to target illicit markets and foreign cartels, a shift that could materially benefit Trulieve’s operations and the broader legal cannabis industry.
The most recent analyst rating on (TSE:TRUL) stock is a Buy with a C$28.00 price target. To see the full list of analyst forecasts on Trulieve Cannabis stock, see the TSE:TRUL Stock Forecast page.
Spark’s Take on TSE:TRUL Stock
According to Spark, TipRanks’ AI Analyst, TSE:TRUL is a Neutral.
Trulieve Cannabis’s stock score is driven by strong technical momentum and positive earnings call highlights, despite challenges in profitability and valuation concerns. The company’s revenue growth and cash flow improvements are notable, but net losses and pricing pressures weigh on the overall score.
To see Spark’s full report on TSE:TRUL stock, click here.
More about Trulieve Cannabis
Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator with leading market positions in Arizona, Florida and Pennsylvania. The company focuses on building scale in retail and distribution through a hub strategy, offering innovative, high-quality cannabis products across a broad brand portfolio to medical patients and adult consumers in regulated U.S. markets.
Average Trading Volume: 243,354
Technical Sentiment Signal: Buy
Current Market Cap: C$2.77B
For detailed information about TRUL stock, go to TipRanks’ Stock Analysis page.